Adaptimmune Annual report pursuant to Section 13 and 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 18,240	$ 20,629	$ 10,414
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	6,264	9,052	4,417
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 11,976	$ 11,577	$ 5,997